Health economics of a hexavalent meningococcal outer-membrane vesicle vaccine in children: Potential impact of introduction in the Dutch vaccination program

Vaccine

Volumn 20, Issue 1-2, 2001, Pages 202-207

  Bos, J M ^a,b   Rumke H C ^a,c   Welte, R ^a   Postma, M J ^b   Jager, J C ^a  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

^c ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

Cost effectiveness; Economic evaluation; Meningococcal disease; Neisseria meningitidis; Vaccination

Indexed keywords

ANTIBIOTIC AGENT; MENINGOCOCCUS VACCINE;

ACUTE DISEASE; ARTICLE; COST EFFECTIVENESS ANALYSIS; DEATH; DRUG EFFICACY; HEALTH ECONOMICS; HUMAN; MEMBRANE VESICLE; MENINGOCOCCOSIS; MODEL; NETHERLANDS; PRIORITY JOURNAL; PROPHYLAXIS; PROSPECTIVE PRICING; QUALITY ADJUSTED LIFE YEAR; SEROTYPE; SIMULATION; VACCINATION;

BACTERIAL OUTER MEMBRANE PROTEINS; CHILD, PRESCHOOL; COMPUTER SIMULATION; COST OF ILLNESS; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; MODELS, THEORETICAL; NETHERLANDS; VACCINATION;

EID: 0035850988     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(01)00254-7     Document Type: Article

References (23)

1. Clinical manifestation and course of meningococcal disease in 562 patients
2. Immunogenicity and safety of a hexavalent meningococcal outer-membrane vesicle vaccine in children of 2-3 years and 7-8 years of age
3. Outcomes of bacterial meningitis; a meta-analysis
4. Bacterial meningitis in the United States in 1995; active surveillance team
5. Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins
6. Epidemic meningococcal disease in New Zealand: Epidemiology and potential for prevention by vaccine
7. Hexavalent meningococcal OMV vaccination results in immunological memory and persistence of PorA specific bactericidal antibodies in children
8. The friction cost method for measuring indirect costs of disease
9. A practical guide for calculating the indirect costs of disease
10. The impact of conjugate group C meningococcal vaccination